| 44.7 -4.16 (-8.51%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 59.12 |
1-year : | 63.63 |
| Resists | First : | 50.61 |
Second : | 54.47 |
| Pivot price | 49.01 |
|||
| Supports | First : | 44.36 |
Second : | 36.91 |
| MAs | MA(5) : | 48.12 |
MA(20) : | 49.93 |
| MA(100) : | 50.71 |
MA(250) : | 56.47 |
|
| MACD | MACD : | -1.2 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 19.4 |
D(3) : | 23.4  |
| RSI | RSI(14): 23.3 |
|||
| 52-week | High : | 69.09 | Low : | 44.36 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BMY ] has closed below the lower bollinger band by 16.2%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 79.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 47.6 - 47.89 | 47.89 - 48.1 |
| Low: | 43.72 - 44.08 | 44.08 - 44.35 |
| Close: | 44.22 - 44.76 | 44.76 - 45.16 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Thu, 25 Apr 2024
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions - Yahoo Finance
Thu, 25 Apr 2024
Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised) - Yahoo Finance
Thu, 25 Apr 2024
Why Bristol Myers Squibb Stock Is Sinking Today - The Motley Fool
Thu, 25 Apr 2024
Why Bristol Myers Squibb Stock Is Sinking Today - Yahoo Finance
Thu, 25 Apr 2024
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat - Yahoo Finance
Thu, 25 Apr 2024
Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript - The Motley Fool
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,030 (M) |
| Shares Float | 2,020 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 78.9 (%) |
| Shares Short | 35,120 (K) |
| Shares Short P.Month | 32,650 (K) |
| EPS | 3.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.56 |
| Profit Margin | 17.8 % |
| Operating Margin | 17 % |
| Return on Assets (ttm) | 5.6 % |
| Return on Equity (ttm) | 26.5 % |
| Qtrly Rev. Growth | 0.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 22.17 |
| EBITDA (p.s.) | 9.07 |
| Qtrly Earnings Growth | -8.9 % |
| Operating Cash Flow | 13,860 (M) |
| Levered Free Cash Flow | 13,780 (M) |
| PE Ratio | 11.58 |
| PEG Ratio | -20.3 |
| Price to Book value | 3.07 |
| Price to Sales | 2.01 |
| Price to Cash Flow | 6.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|